Gilead Sciences
NASDAQ: GILD
$66.94
Closing price January 22, 2021
Tuesday's top analyst upgrades and downgrades included Airbnb, American Express, Arch Capital, Carlyle, Darden Restaurants, Facebook, Eli Lilly and Nio.
3 days ago
Last Updated: 3 days ago
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
11 days ago
Although the markets may be falling, 24/7 Wall St. is taking a look at some big analyst calls that we have seen so far on Monday.
18 days ago
Last Updated: 18 days ago
Thursday's top analyst upgrades and downgrades included AT&T, Boeing, ConocoPhillips, Gilead Sciences, Illumina, Lam Research, Raytheon Technologies and Yum Brands.
1 month ago
Last Updated: 1 month ago
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
1 month ago
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
1 month ago
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
1 month ago
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
1 month ago
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
2 months ago
Last Updated: 2 months ago
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
2 months ago
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
2 months ago
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
2 months ago
Some battered stocks that have not risen back to their highs are attracting some interesting analyst upgrades and new coverage.
3 months ago
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
3 months ago
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.
3 months ago
Get Our Free Investment Newsletter